BCM
AMAG

BlueCrest Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

BlueCrest Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14,231
Closed -$287K – 1984
2018
Q1 		$287K Buy
+14,231
New +$241K 0.01% 1089
2017
Q4 		– Sell
-20,016
Closed -$369K – 1190
2017
Q3 		$369K Buy
+20,016
New +$373K 0.02% 578

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlueCrest Capital Management's AMAG Position: Q2 2018 in Review

BlueCrest Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q2 2018, closing a stake of 14,231 shares — an estimated $287K sold.

BlueCrest Capital Management first reported a position in AMAG in Q3 2017 and held it in 2 quarters. The position peaked at $369K in Q3 2017. 173 funds tracked by Wall St. Rank hold AMAG as of Q2 2018.

  • BlueCrest Capital Management reported no remaining AMAG Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 14,231 AMAG Pharmaceuticals shares in Q2 2018, an estimated $287K.
  • BlueCrest Capital Management first reported a position in AMAG Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's AMAG Pharmaceuticals position peaked at $369K in Q3 2017.
  • 173 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.